CD274 and non-small cell lung carcinoma: Additionally, PD-L1 expression is the most critical indicator for utilizing ICIs, and the PD-L1 expression score is applied in the prescription guide for anti-PD-1 treatment in non-small cell lung cancer, gastric cancer, bladder cancer, etc., but not known for PDAC32.